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Regenerative medicine and stem cell technolo-
gies are estimated to become a $500 billion 
industry over the next 20 years. We are at the 
ground floor of a vastly important field of life 
science discovery. Nations and states are making 
stem cell research a target for economic devel-
opment. The 2008 World Stem Cell Summit will 
present market trends and provide the critical 
tools to evaluate new business opportunities in 
this exciting and burgeoning field.
Presented By:
The Genetics Policy Institute
University of Wisconsin
WiCell Research Center
Learn from the 
World’s Leaders in 
Regenerative Medicine.
Networking and Collaboration
Panel Discussions
Workshops
www.WorldStemCellSummit.com
Register Now: 
The World Stem Cell Summit is the preemi-
nent gathering for the global stem cell 
community with the shared mission to 
advance stem cell research from the labora-
tory to lifesaving treatments.
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Cover image: A section of adult human pancreatic tissue was labeled with anti-islet cell surface marker HPi2 (green), anti-
amylase (red) and Hoechst 33342 (blue). The HPi1/2/3 antibodies specifically recognize islet cells, permitting their separation
from exocrine and other pancreatic cells and isolation for study. 
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